Last reviewed · How we verify
Mupirocin 2% nasal ointement — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Mupirocin 2% nasal ointement (Mupirocin 2% nasal ointement) — Lindenhofgruppe AG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mupirocin 2% nasal ointement TARGET | Mupirocin 2% nasal ointement | Lindenhofgruppe AG | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mupirocin 2% nasal ointement CI watch — RSS
- Mupirocin 2% nasal ointement CI watch — Atom
- Mupirocin 2% nasal ointement CI watch — JSON
- Mupirocin 2% nasal ointement alone — RSS
Cite this brief
Drug Landscape (2026). Mupirocin 2% nasal ointement — Competitive Intelligence Brief. https://druglandscape.com/ci/mupirocin-2-nasal-ointement. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab